What matters most

Key takeaways

  • Each GLP-1 product has its own application, indication, dose, revision date, and prescribing information.
  • Current labels discuss severe gastrointestinal reactions, delayed gastric emptying, aspiration risk, gallbladder disease, pancreatitis, and product-specific eye or retinopathy information.
  • FDA asked manufacturers to remove suicidal-behavior language from three obesity-drug labels in January 2026 after its review found no increased risk.
  • A label change communicates regulated prescribing information; it does not by itself prove when a risk was knowable or what caused one patient's event.

2017 through 2023: different medicines, different approvals

FDA approved Ozempic, injectable semaglutide for type 2 diabetes, in 2017. Rybelsus brought oral semaglutide in 2019. Wegovy received its chronic weight-management approval in 2021. Lilly's tirzepatide entered diabetes treatment as Mounjaro in 2022 and chronic weight management as Zepbound in 2023. These brand names are not interchangeable even when an active ingredient overlaps, because the labeled population, dose, delivery system, benefits, and revision history differ.

The original and later labels have long described common gastrointestinal adverse reactions and class-related warnings such as pancreatitis and gallbladder disease. Semaglutide labels also discuss diabetic-retinopathy complications observed in a diabetes outcomes trial. That warning is distinct from NAION. A timeline must quote the label applicable to the product and date of use; a warning added to one obesity product should not be backdated automatically into every diabetes brand.

2023 and 2024: severe GI reactions and aspiration move into focus

FDA-approved prescribing information evolved as postmarketing experience accumulated. Current Ozempic and Wegovy labels say severe gastrointestinal adverse reactions have been reported and include product-specific language about severe gastroparesis. The labels also explain that semaglutide delays gastric emptying, which can affect absorption of oral medicines. Delayed emptying is a pharmacologic effect; a label statement does not mean every episode of nausea is gastroparesis.

Labels later added warnings about pulmonary aspiration during general anesthesia or deep sedation. Rare postmarketing reports involved residual gastric contents despite preoperative fasting. The labels say available data are insufficient to recommend whether temporarily stopping the medicine or changing fasting guidance reduces the risk. That careful wording matters: a safety signal and precaution can justify communication even when incidence, mechanism, and best prevention strategy are not fully resolved.

2024 to 2026: FDA reviews suicidal thoughts and changes course

In January 2024, FDA said its preliminary evaluation of reports of suicidal thoughts or actions had not found evidence that GLP-1 medicines caused them, while acknowledging that a very small risk could not initially be ruled out. The agency reviewed clinical trials, postmarketing reports, and observational data. This was a class-level safety evaluation, not a decision about a specific plaintiff or a declaration that mental-health symptoms should be ignored.

On January 13, 2026, FDA announced that its comprehensive review did not identify an increased risk and asked application holders to remove suicidal-behavior and ideation language from Saxenda, Wegovy, and Zepbound labeling. The sequence illustrates why warnings are not permanent admissions. Regulators can add, refine, or remove language as evidence changes. Patients with new or worsening mental-health symptoms should still seek care, regardless of whether a particular label carries a dedicated warning.

2025 and 2026 labels: check the exact document

The 2025 Ozempic label revision added prominent severe-GI language and states the medicine is not recommended in patients with severe gastroparesis. Its May 2026 revision retained the core warning structure while reflecting later application changes. Wegovy's 2026 prescribing information addresses its indications and doses, including the higher-dose approval, and carries its own adverse-reaction and anesthesia language. Tirzepatide labels use their own wording and dates.

A label's 'recent major changes' box is useful but not a full historical archive. Sections can change without appearing in that box indefinitely, and Medication Guides summarize rather than replace full prescribing information. For a legal warning question, preserve the PDF revision that was operative during the claimed exposure, the approval letters or supplement history, and the contemporaneous communication. Quoting only today's web page can erase what a prescriber saw years earlier.

What a label can—and cannot—prove

FDA labeling is primary regulatory evidence about approved uses, contraindications, warnings, precautions, adverse reactions, and patient counseling. It can show that FDA required or approved particular language by a revision date. It does not automatically establish that the manufacturer knew the same information at an earlier date, that the wording was legally inadequate under every state's law, or that a listed event was caused by the drug in one patient.

Postmarketing sections often state that voluntary reports come from a population of uncertain size, making frequency and causation difficult to establish. Conversely, a risk need not appear as a boxed warning to matter clinically. The responsible method is product-specific, date-specific, and text-specific. Readers should consult their clinician before stopping a medicine; the risks of untreated diabetes, obesity, cardiovascular disease, or abrupt treatment changes are not answered by a lawsuit page.

Reader questions

Frequently asked questions

Do all GLP-1 drugs have the same warnings?

No. Labels overlap in class effects but differ by active ingredient, indication, dose, evidence, and revision history.

Did FDA remove the suicidal-thoughts warning?

In January 2026, FDA asked holders of Saxenda, Wegovy, and Zepbound applications to remove that language after its review found no increased risk.

Does an adverse event in a label prove causation?

No. Postmarketing reports can support warnings even when frequency or individual causation cannot be reliably determined.

Which label matters for a historical warning claim?

The product-specific prescribing information in effect during the relevant use period is central; today's label may contain later changes.

Primary-source file

Documents and research used

  1. The May 2026 Ozempic prescribing information is that product's own approved label.Ozempic Prescribing Information, May 2026U.S. Food and Drug Administration · accessed
  2. The June 2026 Wegovy prescribing information is that product's own approved label.Wegovy Prescribing Information, June 2026U.S. Food and Drug Administration · accessed
  3. The January 2026 Mounjaro prescribing information is that product's own approved label.Mounjaro Prescribing Information, January 2026U.S. Food and Drug Administration · accessed
  4. The Zepbound prescribing information is that product's own approved label.Zepbound Prescribing InformationU.S. Food and Drug Administration · accessed
  5. FDA published a preliminary evaluation of reported suicidal thoughts with GLP-1 medicines.FDA Preliminary GLP-1 Suicidal Thoughts EvaluationU.S. Food and Drug Administration · accessed
  6. FDA requested removal of the suicidal behavior and ideation warning, a documented labeling change.FDA Requests Removal of Suicidal Behavior and Ideation WarningU.S. Food and Drug Administration · accessed
  7. FDA approved a higher-dose Wegovy presentation, a dated regulatory action.FDA Approves Higher-Dose WegovyU.S. Food and Drug Administration · accessed